Developing remyelinating and neuroprotective therapies for Multiple Sclerosis
Pheno Therapeutics aims to identify novel remyelinating agents and develop transformational therapeutics that enhance the repair of damaged myelin sheaths in Multiple Sclerosis patients.
The company was founded by Advent Life Sciences and the University of Edinburgh to build on the ground breaking research of Prof Siddharthan Chandran and Prof Neil Carragher, world class experts in multiple sclerosis and stem cell biology, and phenotypic screening, respectively.
CEO Fraser Murray
Advent founded Pheno Therapeutics in 2019.
Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease
Press Release. Preclinical program with potential for disease modifying therapeutic Edinburgh, UK January 11 2023 – Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of…Read More